<code id='BF9F033407'></code><style id='BF9F033407'></style>
    • <acronym id='BF9F033407'></acronym>
      <center id='BF9F033407'><center id='BF9F033407'><tfoot id='BF9F033407'></tfoot></center><abbr id='BF9F033407'><dir id='BF9F033407'><tfoot id='BF9F033407'></tfoot><noframes id='BF9F033407'>

    • <optgroup id='BF9F033407'><strike id='BF9F033407'><sup id='BF9F033407'></sup></strike><code id='BF9F033407'></code></optgroup>
        1. <b id='BF9F033407'><label id='BF9F033407'><select id='BF9F033407'><dt id='BF9F033407'><span id='BF9F033407'></span></dt></select></label></b><u id='BF9F033407'></u>
          <i id='BF9F033407'><strike id='BF9F033407'><tt id='BF9F033407'><pre id='BF9F033407'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:focus    Page View:298
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In